Submission of 32nd Annual Report for the Financial Year 2024-25 under Regulation 34 of SEBI (LODR) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Limited has submitted its 32nd Annual Report for FY 2024-25 to BSE, dispatched to shareholders on August 28, 2025. The 32nd Annual General Meeting is scheduled for Friday, September 19, 2025 at 3:00 PM via video conferencing. The AGM notice includes several key items: appointment of a new secretarial auditor (Aakanksha Dubey & Co.) for a 5-year term, regularization and appointment of multiple directors as Whole-Time, Non-Executive, and Independent Directors for 5-year terms, and approval to borrow funds up to Rs. 200 Crores. Material related party transactions with its holding company Virupaksha Organics Limited are also up for shareholder approval, including sales/purchases up to Rs. 200 Crores and loans/guarantees up to Rs. 100 Crores. Notably, all current directors on the board are presently designated as 'Additional Directors,' meaning their formal regularization requires shareholder approval at this AGM. Cost auditor remuneration of Rs. 65,000 for FY 2025-26 is also up for ratification.
Routine regulatory compliance filing — no direct positive or negative impact on shareholders. Shareholders should review the proposed borrowing limit (Rs. 200 Crores) and significant related party transactions with the holding company Virupaksha Organics Limited before voting at the AGM on September 19, 2025.